PFKFB3 and colorectal carcinoma: Xiao et al. demonstrated that miR-1915-3p can improve the chemotherapeutic efficacy of oxaliplatin in CRC cells by suppressing EMT-promoting oncogenes, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), and ubiquitin specific peptidase 2 (USP2) [101].